Clinical TrialTreatment-Resistant Depression (TRD)Completed

Pharmacogenetics Associated With IV Ketamine

Prospective observational study (n=85 actual) collecting saliva genetic samples from adults who previously received IV ketamine for treatment-resistant depression to correlate genetic biomarkers with treatment response.

Target Enrollment
85 participants
Study Type
Phase NA observational
Design
Non-randomized

Detailed Description

Participants who previously received intravenous ketamine for treatment-resistant depression provide two saliva swabs for genetic analysis; the study examines associations between genetic markers and clinical response to IV ketamine.

Observational, prospective design leveraging clinic-treated patients at the Canadian Rapid Treatment Centre of Excellence; outcomes are biomarker–response correlations rather than interventional efficacy.

Study Arms & Interventions

Genetic samples

experimental

Participants who previously received IV ketamine provide saliva for genetic analysis to correlate biomarkers with treatment response.

Interventions

  • Compound

    Saliva genetic samples: two saliva swabs collected; genetic analysis only.

Participants

Ages
18 – 65
Sexes
Male & Female

Inclusion Criteria

  • Inclusion Criteria:
  • 1. Must have received IV ketamine previously to treat Treatment-Resistant Depression
  • 2. Between the ages of 18-65 years old.
  • 3. Clinical diagnosis of MDD
  • 4. Individuals may have had comorbid psychiatric conditions (e.g., anxiety), but the comorbid psychiatric condition cannot be the primary clinical concern.
  • 5. Ability to provide informed consent

Exclusion Criteria

  • Exclusion Criteria:
  • 1. Individuals who meet DSM 5 criteria for a substance use and/or alcohol use disorder in the past 3 months.
  • 2. Individuals who are currently experiencing psychotic symptoms as part of an MDE (mood congruent/mood incongruent).
  • 3. Individuals who are unable to consent to the procedure.
  • 4. Individuals who are unable to adhere to the protocol in its totality

Study Details

Locations

Canadian Rapid Treatment Centre of Excellence — Mississauga, Ontario, Canada

Your Library